none, . none ., 2017. Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum. International Journal of Surgery: Oncology, 2(9), p.e40. DOI: http://doi.org/10.1097/IJ9.0000000000000040

none none. Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum. International Journal of Surgery: Oncology. 2017;2(9):e40. DOI: http://doi.org/10.1097/IJ9.0000000000000040

none, . none . (2017). Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum. International Journal of Surgery: Oncology, 2(9), e40. DOI: http://doi.org/10.1097/IJ9.0000000000000040

none none, ‘Sulfonylureas (not Metformin) Improve Survival of Patients with Diabetes and Resectable Pancreatic Adenocarcinoma: Erratum’ (2017) 2 International Journal of Surgery: Oncology e40 DOI: http://doi.org/10.1097/IJ9.0000000000000040

none, none. 2017. “Sulfonylureas (not Metformin) Improve Survival of Patients with Diabetes and Resectable Pancreatic Adenocarcinoma: Erratum”. International Journal of Surgery: Oncology 2 (9): e40. DOI: http://doi.org/10.1097/IJ9.0000000000000040

none, none. “Sulfonylureas (not Metformin) Improve Survival of Patients with Diabetes and Resectable Pancreatic Adenocarcinoma: Erratum”. International Journal of Surgery: Oncology 2, no. 9 (2017): e40. DOI: http://doi.org/10.1097/IJ9.0000000000000040

none, . none .. “Sulfonylureas (not Metformin) Improve Survival of Patients with Diabetes and Resectable Pancreatic Adenocarcinoma: Erratum”. International Journal of Surgery: Oncology, vol. 2, no. 9, 2017, p. e40. DOI: http://doi.org/10.1097/IJ9.0000000000000040